



Alzero

(Levocetirizine 5mg)

Zeroes Down Allergy

Clinical Study

J Allergy Clin Immunol. 2004 Apr;113(4):669-76

Levocetirizine better protects than desloratadine in a nasal provocation with allergen.

Deruaz C, Leimgruber A, Berney M, Pradervand E, Spertini F.

Division of Allergy and Immunology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon, 1011 Lausanne, Switzerland.

BACKGROUND: Direct comparisons of antihistamines are rare but very much needed. Newly available antihistamine preparations, levocetirizine, the R-enantiomer of racemate cetirizine, and desloratadine, an active metabolite of loratadine, have been recently released for allergic rhinitis. **OBJECTIVE:** We sought to compare levocetirizine and desloratadine in a nasal provocation test (NPT) with grass pollen.

METHODS: Twenty-four volunteers with grass pollen allergy and a history of rhinitis were enrolled in a double-blind, placebo-controlled, crossover study. Three NPTs were performed in a dose-escalating manner during the out-of-season period 4 hours after a single dose of levocetirizine (5 mg), desloratadine (5 mg), or placebo.

RESULTS: CONCLUSIONS: **This study demonstrates a better overall protection of a single dose of levocetirizine compared with desloratadine in an NPT with grass pollen allergen.** In contrast to late-phase inflammatory markers, which were unaffected, extravascular leakage of the early-phase marker albumin was significantly limited by levocetirizine.

Alzero

- *Twice as potent as cetirizine*
- *Greater decongestant activity than desloratadine*

Highly effective in

- Allergic Rhinitis
- Rhinorrhoea
- Allergic Bronchitis
- Asthma



For further information please contact us at:

Indchemie
Health Specialities Pvt. Ltd.

117, T.V. Industrial Estate, Worli, Mumbai- 400 030 © Registered Trade Mark